Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Novel Epothilone (BMS-247550) in Patients with Metastatic Breast Cancer (MBC) Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Novel Epothilone (BMS-247550) in Patients with Metastatic Breast Cancer (MBC) conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Novel Epothilone (BMS-247550) in Patients with Metastatic Breast Cancer (MBC) Clinical research trials and Novel Epothilone (BMS-247550) in Patients with Metastatic Breast Cancer (MBC) healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Novel Epothilone (BMS-247550) in Patients with Metastatic Breast Cancer (MBC). Novel Epothilone (BMS-247550) in Patients with Metastatic Breast Cancer (MBC) Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Novel Epothilone (BMS-247550) in Patients with Metastatic Breast Cancer (MBC) clinical trial. Human subjects often obtain the finest healthcare possible for their Novel Epothilone (BMS-247550) in Patients with Metastatic Breast Cancer (MBC) condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.

Home > "N" Clinical Trials Conditions > Novel Epothilone (BMS-247550) in Patients with Metastatic Breast Cancer (MBC)

Novel Epothilone (BMS-247550) in Patients with Metastatic Breast Cancer (MBC)



Novel Epothilone (BMS-247550) in Patients with Metastatic Breast Cancer (MBC)

For Condition: Metastatic breast cancer
Status: Recruiting
Sponsor(s): Bristol-Myers Squibb ,
Synopsis: The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.
Details:
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: - Patients must have received all 3 drugs- an anthracycline, taxane, and capecitabine (alone or in combination) and be resistant - No more than 3 prior chemotherapy regimens in the metastatic setting - Must have at least one target lesion that is radiograpically measurable - Good performance status - No history of or current brain or leptomeningeal disease
Total Enrollment: 

Location and Contact Information:

Various locations within the US and Canada *Recruiting*
Call for information,  New Jersey, 
United States
Recruiting Bristol-Myers  Call Center 1-866-892-1BMS


Additional Information:
Study ID Numbers:  CA163-081; 
Study Start Date: March 2004
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00080262

Other Metastatic Breast Cancer Studies:
1. Pegylated Liposomal Doxorubicin compared to Capecitabine in treating Women 65 Years and Older with Metastatic Breast Cancer

2. An Investigational Drug versus Capecitabine in Male or Female Patients with Advanced Breast Cancer

3. Phase 2 randomized, placebo-controlled, double blind study of study drug in combination with Docetaxel versus Docetaxel alone for patients with Metastatic Breast Cancer.

4. Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer

5. Novel Epothilone (BMS-247550) in Patients with Metastatic Breast Cancer (MBC)

Related Studies:

Other Metastatic breast cancer Clinical Trials
Other New Jersey Clinical Trials
Other Call for information Clinical Trials

Novel Epothilone (BMS-247550) in Patients with Metastatic Breast Cancer (MBC)
Modify your Search

  Other Metastatic breast cancer Clinical Trials
  Other New Jersey Clinical Trials
  Other Call for information Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103